Downstream Effectors of ILK in Cisplatin-Resistant Ovarian Cancer

Despite good responses to first-line treatment with platinum-based combination chemotherapy, most ovarian cancer patients will relapse and eventually develop platinum-resistant disease with poor prognosis. Although reports suggest that integrin-linked kinase (ILK) is a potential target for ovarian c...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Cancers (Basel)
Main Authors: Reyes-González, Jeyshka M., Quiñones-Díaz, Blanca I., Santana, Yasmarie, Báez-Vega, Perla M., Soto, Daniel, Valiyeva, Fatima, Marcos-Martínez, María J., Fernández-de Thomas, Ricardo J., Vivas-Mejía, Pablo E.
Format: Artigo
Jezik:Inglês
Izdano: MDPI 2020
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7226328/
https://ncbi.nlm.nih.gov/pubmed/32260415
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12040880
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki